Kihara James 4
4 · ACADIA PHARMACEUTICALS INC · Filed Apr 7, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) Principal Accounting Officer Kihara Sells Shares
What Happened
Kihara James, ACADIA Pharmaceuticals’ Principal Accounting Officer, sold 1,030 shares in an open-market transaction on April 7, 2026, at a weighted average price of $22.20 per share for proceeds of $22,866. The Form 4 also reports a conversion/exercise event on April 5, 2026 for 2,010 restricted stock units (RSUs) that vested and converted into common shares; a portion of those shares were immediately disposed/withheld to cover taxes.
Key Details
- Transaction dates: RSU conversion/exercise on 2026-04-05; open-market sale on 2026-04-07.
- Sale: 1,030 shares sold at a weighted average price of $22.20; total proceeds $22,866. (Sales executed at prices ranging $22.07–$22.20.)
- Derivative/vesting: 2,010 RSUs converted/settled on 2026-04-05; a reported disposition of 2,010 shares at $0.00 reflects shares withheld/surrendered for tax withholding.
- Footnotes: RSUs represent a contingent right to one share each (F1); mandatory sales were to cover withholding/tax items and intended to comply with Rule 10b5‑1(c) (F2); RSUs vest in four equal annual installments beginning April 5, 2023 (F4).
- Shares owned after the transactions: Not disclosed in the Form 4.
- Filing timeliness: Report filed 2026-04-07 for transactions on 2026-04-05—filed within the usual Form 4 reporting window (timely).
Context
This filing shows RSU vesting and associated tax-related transactions rather than an independent, discretionary investment decision. The exercise/conversion of RSUs and the subsequent sale/withholding to satisfy taxes is common executive compensation administration and is often reported as a conversion (derivative) plus a sale or surrender of shares.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-04-05+2,010→ 28,895 total - Sale
Common Stock
[F2][F3]2026-04-07$22.20/sh−1,030$22,866→ 27,865 total - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-04-05−2,010→ 0 total→ Common Stock (2,010 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.07 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The restricted stock units vest in four equal annual installments beginning April 5, 2023.